Three new articles in the Journal of Oncology Practice take close look at the issue of risk/benefit and “value” in the management of prostate cancer today — and the management of advanced disease in particular. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen, cardiocascular, cost, deprivation, effect, metabolic, outcome, sie, value | 7 Comments »
According to a newly published study of data from > 285,000 European males (the Metabolic Syndrome and Cancer Project), men with metabolic aberrations are at slightly less risk for a diagnosis of prostate cancer compared with men who have normal levels of metabolic factors … but their risk for prostate cancer-specific mortality is similar. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Risk | Tagged: aberrant, BMI, body mass index, Diagnosis, metabolic, mortality, risk | Leave a comment »
Over a month ago we reported on a paper by Häggström et al. that noted an increased risk of death among patients with prostate cancer and metabolic syndrome. … READ MORE …
Filed under: Living with Prostate Cancer, Management | Tagged: metabolic, mortality, risk, syndrome | Leave a comment »
According to an article due to be published on line today in Cancer, a group of clinical characteristics commonly referred to as “metabolic syndrome” are strongly associated with an increased risk for prostate cancer-specific mortality among men diagnosed with prostate cancer, but are not associated with an increased risk for the initial diagnosis. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: metabolic, mortality, risk, syndrome | Leave a comment »
According to a media release from the U.S. Food and Drug Administration (FDA) yesterday, the agency has asked manufacturers of the class of drugs known as luteinizing hormone-releasing hormone (LHRH) or gonadotropin-releasing hormone (GnRH) agonists to include warnings about risk for cardiovascular disease and diabetes in product labeling for these drugs. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: agonist, cardiovascular, GnRH, LHRH, metabolic, risk, side effect | 3 Comments »
For many years it has been understood by specialists that hormonal treatment of prostate cancer patients with luteinizing hormone releasing hormone (LHRH) agonists — also known as gonadatropin releasing hormone or GnRH agonists — is associated with metabolic side effects that include risks for cardiovascular disease and diabetes. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: agonist, androgen deprivation therapy, cardiovascular, GnRH, LHRH, metabolic, side effect | 1 Comment »
For those who may have been tempted by some of the more extreme forms of “metabolic” or “nutritional” therapies as a means to treat or prevent prostate cancer, we recommend reading a brief (and patient friendly) article in this month’s issue of Oncology. … READ MORE …
Filed under: Management, Prevention, Treatment | Tagged: metabolic, nutritional, therapy | Leave a comment »
This morning’s news update deals with two newly published studies:
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, adverse, androgen, artificial, cancer, cardiovascular, deprivation, effects, hypogonadism, incontinence, metabolic, news, prostate, sphincter, update | 2 Comments »
News and information provided on this site should not be used for diagnosing or treating any health problem or disease.
The “New” Prostate Cancer InfoLink is intended for informational purposes only. It is not engaged in rendering medical advice or professional services and is not a substitute for professional care. If you have or suspect you may have a health problem, please consult your healthcare provider.
Blog at WordPress.com. WP Designer.
THE "NEW" PROSTATE CANCER INFOLINK